Impact BioMedical Inc. has announced the completion of a reverse stock split of its common stock, effective September 23, 2026. The company filed a Certificate of Amendment with the Secretary of State of Nevada to effect a one-for-twelve point six two (1-for-12.62) split. As a result, every 12.62 shares of the company's issued and outstanding common stock were automatically combined into one share of outstanding common stock.
The reverse split reduced the number of shares issued and outstanding from approximately 107.8 million to approximately 8.6 million. The par value of the common stock remains $0.001 per share, and the authorized number of shares was not changed. The split did not alter the voting rights of the common stock.
Trading of the company's common stock began on a split-adjusted basis on September 23, 2026, under the existing ticker symbol "IBO" on the New York Stock Exchange American. The company also noted a new CUSIP number of 45259L304 has been assigned.
Impact BioMedical explained that the split was approved by the Board of Directors on November 24, 2025, and subsequently approved by the majority of the company's stockholders on December 30, 2025. The company noted that a clerical processing error in the office of the Secretary of State of Nevada delayed the receipt of the file-stamped Amendment until October 6, 2026, necessitating the filing of this current report.
The company’s transfer agent, Equiniti Transfer & Trust Company, is acting as the exchange agent for the reverse stock split. Registered stockholders holding shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders holding shares through a broker, bank, trust, or other nominee will have their positions automatically adjusted to reflect the split.
